Aquestive Therapeutics Posts 10% Q4 Revenue Gain, Secures RTW Funding for Anaphylm
Aquestive Therapeutics reported a 10% rise in Q4 2025 revenues, driven by manufacturing and supply growth, while net loss widened due to higher SG&A and legal expenses. The company secured RTW funding and plans a 50% sales force expansion following NDA resubmission, with an FDA Type A meeting expected soon.
1. Q4 2025 Financial Performance
Aquestive reported total revenues of $XX million in Q4 2025, marking a 10% increase from a year earlier driven by manufacturing and supply contracts. However, net loss widened from $YY million to $ZZ million due to elevated selling, general and administrative expenses and increased legal costs.
2. Anaphylm Development Path
Management has submitted a request for a Type A meeting with the FDA to align on trial design modifications for Anaphylm’s NDA resubmission. Key regulatory discussions are expected within 30 days, aiming to clarify study protocols and approval requirements.
3. RTW Funding Extension
An extended financing agreement with RTW has secured additional capital earmarked for the commercial launch of Anaphylm. This funding provides runway for launch preparations and potential scale-up of manufacturing and marketing activities.
4. Commercial and Team Expansion
Upon approval of Anaphylm, Aquestive plans to expand its sales force by 50%, increasing headcount to 75 representatives targeting allergists and pediatricians. The company also bolstered its clinical team with Dr. Matt Greenhawt and Dr. Matthew Davis to support development and FDA interactions.